Nathan D. Wong

University of California, Irvine

Author of 4 Presentation(s)

32. Prevention: Clinical 1030-05

1030-05 - TOTAL ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) RESIDUAL RISK ASSOCIATED WITH INCREASED LIPOPROTEIN(A) LEVELS AMONG STATIN TREATED ADULTS WITH CARDIOVASCULAR DISEASE

Session
1030 - Lipoprotein Little (a): From "little a" to "Big A"
Speakers
Pathway
32. Prevention: Clinical
Presentation Number
1030-05
Presentation Rating
 Not Rated
32. Prevention: Clinical 1263-090
32. Prevention: Clinical 1263-108
02. Acute and Stable Ischemic Heart Disease: Clinical 1466-149

1466-149 - N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE IN THE PREDICTION OF REDUCED CORONARY FLOW VELOCITY RESERVE IN ASYMPTOMATIC TYPE 2 DIABETIC PATIENTS

Session
1466 - Acute and Stable Ischemic Heart Disease: Clinical 8
Pathway
02. Acute and Stable Ischemic Heart Disease: Clinical
Presentation Number
1466-149
Presentation Rating
 Not Rated

Author of 1 Presentation

32. Prevention: Clinical 1030-05

1030-05 - TOTAL ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) RESIDUAL RISK ASSOCIATED WITH INCREASED LIPOPROTEIN(A) LEVELS AMONG STATIN TREATED ADULTS WITH CARDIOVASCULAR DISEASE

Session
1030 - Lipoprotein Little (a): From "little a" to "Big A"
Speakers
Pathway
32. Prevention: Clinical
Presentation Number
1030-05
Presentation Rating
 Not Rated

Author of 3 Presentation(s)

32. Prevention: Clinical 1263-090
32. Prevention: Clinical 1263-108
02. Acute and Stable Ischemic Heart Disease: Clinical 1466-149

1466-149 - N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE IN THE PREDICTION OF REDUCED CORONARY FLOW VELOCITY RESERVE IN ASYMPTOMATIC TYPE 2 DIABETIC PATIENTS

Session
1466 - Acute and Stable Ischemic Heart Disease: Clinical 8
Pathway
02. Acute and Stable Ischemic Heart Disease: Clinical
Presentation Number
1466-149
Presentation Rating
 Not Rated